Analysis of the application effect of sacubitril-valsartan in the treatment of coronary heart disease combined with chronic heart failure based on cardiac function and IGFBP7,sST2, CGRP,and ET
Objective To analyze the efficacy of treatment with sacubitril valsartan in patients with coronary heart disease (CHD) combined with chronic heart failure (CHF). Methods From January 2020 to January 2023,86 patients with CHD complicated by CHF were selected at our hospital. They were ran-domly divided into two groups:the control group and the experimental group,each consisting of 43 patients. Both groups received treatment for CHD with nitrates ,statins and antiplatelet agents. The control group was treated for CHF with candesartan ester tablets,aldosterone receptor antagonists and beta-blockers,while the experimental group replaced candesartan ester tablets with sakubatrizol valdecoxib sodium tablets. The effica-cy,adverse effects,cardiac function indexes[including left ventricular short-axis shortening(LVFS),left ventricular ejection fraction(LVEF),and 6-minute walking distance(6 MWD)],ventricular remodeling in-dexes[such as pre-collagenⅢ peptide(PⅢP),laminin(LN),and matrix metalloproteinase-9(MMP-9)], as well as indexes related to myocardial injury and vascular endothelial function [such as insulin-like growth factor-binding protein 7(IGFBP7),soluble growth-stimulated expression gene 2(sST2),calcitonin gene-re-lated peptide(CGRP),and endothelin(ET)],were compared between the two groups. Results The total ef-fective rate was higher in the test group after 3 months of treatment compared with the control group (P<0.05). LVFS,LVEF,6 MWD,and IGFBP7,CGRP were elevated after 3 months of treatment in both groups compared with pre-treatment and were higher in the experimental group compared with the control group. PⅢP, LN,MMP-9,sST2,and ET were lowered,and were lower in the experimental group compared with the con-trol group(P<0.05). There was no difference in the comparison of the total incidence of adverse reactions be-tween the two groups(P>0.05). Conclusion Sacubitril valsartan is used to treat CHD in combination with CHF. It effectively regulates patients' IGFBP7,sST2,CGRP,and ET levels,improving vascular endothelial function,myocardial injury,ventricular remodeling and cardiac function. This,in turn,enhances the efficacy of the treatment and has a good safety profile.
万方数据
维普
